Surgical options for localized and advanced gastrointestinal stromal tumors
β Scribed by Timothy L. Frankel; Alfred E. Chang; Sandra L. Wong
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 236 KB
- Volume
- 104
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
The development of imitinab has led to a revolution in the management of gastrointestinal stromal tumors (GIST), but surgical resection remains the cornerstone of treatment for patients with localized disease. The principles to surgical treatment of GIST include careful handling of tissues to prevent tumor rupture and resection to negative margins without the need for wide excision. Minimally invasive techniques have proven equally efficacious provided appropriate oncologic resections are performed. J. Surg. Oncol. 2011; 104:882β887. Β© 2011 Wiley Periodicals, Inc.
π SIMILAR VOLUMES
## Abstract Progression on firstβline therapy with imatinib in gastrointestinal stromal tumors (GIST) is caused by either initial resistance or more often a secondary mutation in tyrosine kinases KIT or PDGFR. Therapies in development for imatinibβresistant GIST include agents that target KIT/PDGFR
## Abstract Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract. These tumors span a wide clinical spectrum from benign to malignant and have long been recognized for their nearly absolute resistance to chemotherapy and radiation treatment. We revie